FDA Says Fenoglide Exit Wasn't Safety Scare – Generics Safe
Published Date: 4/30/2026
Notice
Summary
The FDA has confirmed that FENOGLIDE tablets (40 mg and 120 mg) were not taken off the market because of safety or effectiveness problems. This means generic drug makers can keep getting approval to sell their versions, keeping options open for patients and pharmacies. No changes in cost or availability are expected, so everyone can breathe easy!
Analyzed Economic Effects
3 provisions identified: 2 benefits, 1 costs, 0 mixed.
Generic Approvals May Continue
The FDA determined that FENOGLIDE (fenofibrate) tablets, 40 mg and 120 mg, were not withdrawn for reasons of safety or effectiveness. Because of that determination, the Agency will not begin procedures to withdraw approval of existing abbreviated new drug applications (ANDAs) that refer to this product, and additional ANDAs referring to the product may be approved if they meet legal and regulatory requirements.
Patient Access and Market Options Preserved
FDA confirmed FENOGLIDE (fenofibrate) tablets, 40 mg and 120 mg, were not removed for safety or effectiveness, and the product remains listed in the Orange Book's "Discontinued Drug Product List" as discontinued for reasons other than safety or effectiveness. The notice says FDA will continue to approve ANDAs that refer to this product when they meet requirements, so patients and pharmacies keep options for generic versions.
ANDA Applicants May Need Updated Labeling
The FDA said that if it determines labeling for FENOGLIDE should be revised to meet current standards, the Agency will advise ANDA applicants to submit such labeling. This informs generic applicants they may be asked to update labeling to conform with current requirements.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-20848, Use of Salt Substitutes To Reduce the Sodium Content in Standardized Foods
The FDA is changing food rules to allow salt substitutes in many standardized foods, helping companies make lower-sodium options. This move aims to cut heart disease risks by reducing sodium without changing how foods basically taste or look. The new rule kicks in December 14, 2026, and food makers have until November 12, 2026, to raise any concerns, with no big costs expected.
2026-16296, Substances Generally Recognized as Safe
The Food and Drug Administration (FDA or we) is proposing to require the submission of generally recognized as safe (GRAS) notices for the use of a human or animal food substance purported to be GRAS under the conditions of its intended use under the Federal Food, Drug, and Cosmetic Act (FD&C Act).
2026-14073, Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign Establishments
The FDA wants to make it easier for drug makers who work in several locations to register as one company instead of many. They’re also updating rules for foreign drug companies to match new laws about handling health threats. If you’re in drug manufacturing, get ready to comment by September 11, 2026, and keep an eye on possible paperwork changes that could affect your business.
2026-13047, Establishment Registration and Product Listing for Tobacco Products
The FDA wants to make sure all tobacco product makers, both in the U.S. and abroad, register their businesses and list their products. This new rule closes a big gap by including foreign companies, helping the FDA keep better track of tobacco products for public health. Comments on this proposal are open until September 14, 2026, so affected businesses should get ready to update their info and possibly face new costs.
2025-04978, Nonprescription Drug Product With an Additional Condition for Nonprescription Use
The FDA is delaying a new rule about nonprescription drugs that have extra conditions for use. Originally set to start on March 21, 2025, the rule’s start date is now pushed back to May 27, 2025, to allow more time for review. This affects drug makers and consumers by giving everyone extra time to prepare for the new requirements without any immediate cost changes.
2025-01840, Nonprescription Drug Product With an Additional Condition for Nonprescription Use
The FDA’s new rule about nonprescription drugs needing extra conditions before use was set to start on January 27, 2025, but it’s now delayed until March 21, 2025. This delay follows a presidential order to pause and review new rules before they take effect. Drug makers, sellers, and consumers should note the new start date and get ready for the updated rules soon.
Previous / Next Documents
Previous: 2026-08389, Self-Regulatory Organizations; The Fixed Income Clearing Corporation; Notice of No Objection To Advance Notice To Raise Prefunded Default Liquidity Through the Commercial Paper Program
The Fixed Income Clearing Corporation (FICC) got the green light to raise up to $10 billion by selling short-term commercial paper to big investors. This extra cash will boost FICC’s safety net to handle member defaults and keep the financial system steady. The change kicks in soon, helping FICC stay ready for any surprises in the market.
Next: 2026-08391, Agency Information Collection Activities; Renewal of an Approved Information Collection Request: Training Certification for Drivers of Longer Combination Vehicles
The FMCSA is renewing its approval to collect info on training certificates for drivers of longer combination vehicles (LCVs). This affects LCV drivers, training providers, and motor carriers who must keep and show these certificates when asked. No big changes or costs are expected, but comments are open until June 1, 2026.